Cardinal Health Earnings Preview (August 11): The Tightest Consensus Of The Week, And A Whisper 13% Above It

TL;DR

• Cardinal Health reports fiscal Q4 2026 on Tuesday, August 11, before the New York open, closing a fiscal year that management has already raised guidance on twice.
• Consensus is $2.42 of adjusted EPS on about $65.1 billion of revenue, and the striking part is the spread: 15 analysts covering a $0.07-wide band, $2.39 to $2.46. That is the tightest consensus on this week's calendar by a distance.
• The computed whisper is $2.73, about 13% above consensus, because Cardinal has posted a median surprise near 12% across its last four prints. A company that beats by double digits every quarter does not have a $0.07 outcome distribution.
• The reason this is knowable is that three quarters are already reported. FY26 non-GAAP EPS guidance was raised in April to $10.70-$10.80, up 30-31%, after fiscal Q3 delivered non-GAAP EPS of $3.17, up 35%, on revenue of $60.9 billion, up 11%.
• Options price only a 6.2% move against a $236.40 spot. The tradeable content is not the quarter, it is the first fiscal 2027 guide issued alongside it.

When Does Cardinal Health Report Earnings?

The short answer: Tuesday, August 11, before the market opens. Tuesday is the densest day of the week, sharing the tape with Sea Limited, CoreWeave and Super Micro; the whole slate is in the earnings calendar.

The Board

A seven-cent consensus band around a company that has beaten by roughly 12% four quarters running.

A $0.07 Consensus Is A Statement About Analysts, Not About The Business

Fifteen sell-side models, all within seven cents of each other. That is not fifteen independent forecasts, that is fifteen models anchored to the same company guidance and to each other. It happens in distribution because the gross margin is thin and stable and the revenue line is close to mechanical: $65 billion of drugs move, a fraction of a point sticks.

The problem is that the same tightness makes the published number a bad bar. Cardinal's median surprise across its last four prints is about 12.4%, and estimates drifted up a cent over the past 30 days. Compound those and the whisper lands at $2.73. The stock does not trade against $2.42; it trades against something closer to the whisper, which is exactly the mechanism that produces the "beat and fall" reaction our earnings calendar exists to make visible.

Anyone reading a headline on Tuesday morning that says Cardinal beat by nine cents should note that nine cents is a 3.7% beat against a company that has been running at 12%.

The Quarter Is Already Three-Quarters Known

This is what makes the print low-variance. Work forward from disclosure:

• FY2026 non-GAAP EPS guidance: $10.70-$10.80, raised and narrowed on April 30, representing 30-31% growth.
• Fiscal Q3 delivered $3.17 of non-GAAP EPS, up 35%, on $60.9 billion of revenue, up 11%.
• Segment guidance behind the raise: Pharmaceutical and Specialty Solutions segment profit up 22-23% (from 20-22%), Other segment profit up 36-38% (from 33-35%).
• Subtract the consensus fourth quarter of $2.42 from the full-year range and the first nine months implied are $8.28-$8.38. That reconciles with what has been reported, which is the internal-arithmetic check clearing.

The GAAP line will look worse and it should be read carefully rather than reacted to. Fiscal Q3 GAAP operating earnings fell 30% to $509 million and GAAP diluted EPS fell 20% to $1.69, because of a $184 million pre-tax goodwill impairment in the Navista and ION reporting unit. The stock fell about 5.8% on that release even as guidance went up, which is a fair summary of how this name trades: the market does not fully trust the adjustments.

Where The Growth Is Actually Coming From

Drug distribution is a scale business with a 1%-ish operating margin, and nobody re-rates it. What has re-rated Cardinal is the second engine: specialty. The Solaris integration and the Specialty Alliance physician network push the company up the value chain from moving boxes to servicing oncology and other high-cost therapeutic areas, where the fee pools are larger and stickier.

That is the honest bull case and it comes with an honest bear case attached. The $184 million goodwill impairment landed in Navista and ION, which are exactly the specialty-adjacent assets the growth story rests on. Management's read is that segment profit is compounding in the low twenties; the impairment says at least one acquired piece has not performed to the plan it was bought on. Both statements can be true, and Tuesday's segment detail is where the market decides which one dominates.

Fiscal 2027 Guidance Is The Actual Event

At a 6.2% implied move on a $236.40 stock, the option market is pricing about $14.66 of range, and almost all of that risk sits in the forward number rather than the backward one.

What to watch in the first FY27 guide:

• Whether double-digit EPS growth is guided at all after two years of 30%-plus. Lapping a 30% year is the hardest thing a compounding distributor has to do.
• Specialty segment profit growth, and whether the 22-23% run rate is guided to persist.
• Buyback cadence. FY26 repurchases reached $1.0 billion, including an incremental $250 million in the third quarter. Buybacks have been doing visible work on the per-share line, and a step down is a quiet guidance cut.

The Options Angle

A 6.2% implied move on a low-beta distributor whose quarter is largely pre-determined is not obviously cheap, and the risk is one-sided in an unusual way: the beat is close to a formality, the guide is not.

• The straddle is a pass. The quarter cannot surprise by much; the guide can, but a straddle pays for two tails and the downside tail here is a guidance disappointment on a stock that has already run.
• Long shares into the print is the position I want, sized as a hold rather than a trade. The company enters with raised guidance, a 12% habitual surprise, $1 billion of annual buyback and a specialty engine growing at three times the group rate.
• A covered call is defensible here, and this is one of the few names this season where I would say so. The whole position is low-volatility, the implied move is modest, and the upside case is a grind rather than a gap. That is the setup covered calls are actually for.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Breakeven
1	Bullish	Long shares into the print	n/a	n/a	$236.40, Aug 7 close	±6.2%	Scored against the Aug 11 close
2	Neutral to bullish	Covered call	Aug 14 strikes above $250	Live premium not sourced	$236.40, Aug 7 close	±6.2%	Scored on the whole position, not the leg
3	Pass	Long straddle	$237.50 straddle, Aug 14	~6.2% of spot	$236.40, Aug 7 close	±6.2%	Needs a move beyond $221.74 or $251.06

The One-Line Read

Cardinal Health walks into Tuesday with three quarters banked, raised guidance, a seven-cent consensus band and a whisper thirty-one cents above it, so the beat is close to arithmetic and the only thing that can genuinely move the stock is the first fiscal 2027 guide.